Expression of microRNA‑184 in glioma
- Authors:
- Published online on: November 13, 2017 https://doi.org/10.3892/ol.2017.7395
- Pages: 727-730
-
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The aim of the present study was to examine the expression of microRNA (miRNA)‑184 in gliomas with different pathological grades, and its effect on survival prognosis. For the present study, 40 participants were selected with different pathological grades of glioma tissues with grade I (n=10), grade II (n=8), grade III (n=16), and grade IV (n=6). In addition, 10 cases of normal brain tissue (obtained by decompression because of traumatic brain injury) were selected. RT‑PCR and immunohistochemical techniques were used to detect the expression level and intensity of miRNA‑184 in different grades of glioma tissues. The length of survival of miRNA‑184‑positive patients was analyzed. miRNA‑184 mRNA expression was found in normal tissues and tumor tissues, and the expression in tumor tissues was significant (P<0.05). Statistically significant differences of miRNA‑184 expression were observed among different grades (P<0.05). miRNA‑184 expression increased with the increase of grade level. The differences in expression across grade levels was statistically significant (P<0.05). A positive expression was not related to the pathological types of glioma cells. The median survival time of patients with miRNA‑184‑positive expression was significantly shorter than that of the negative expression group (P<0.05). miRNA‑184 is highly expressed in gliomas, which is positively correlated with pathological grade, and is not correlated with pathological type, and negatively correlated with survival time. Thus, miRNA‑184 is a potentially important molecular marker for glioma.
